FOLH1 and neoplasm: Preclinical tPDT using the PSMA ligand YC-9 by Chen et al. resulted in significant tumor growth delay and increased the median survival of the PC3-PIP tumor mice compared to control groups, including untreated, light alone, and YC-9-alone groups [22].